Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rohit Katial

Showing results (41-50 of 61) with videos related to

Pageof 7
Sort By:
The Journal of Allergy and Clinical Immunology. in Practice|April 20, 2026
Dupilumab sustains efficacy despite LABA and ICS withdrawal in patients with asthma: a post hoc analysisMichael E Wechsler, Arnaud Bourdin, Klaus F Rabe, et al.
The Journal of Allergy and Clinical Immunology|July 23, 2013
Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophiliaMichel Laviolette, David L Gossage, Gail Gauvreau, et al.
The Journal of Allergy and Clinical Immunology|January 23, 2018
Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthmaSteven F Weinstein, Rohit Katial, Shyamalie Jayawardena, et al.
The Journal of Allergy and Clinical Immunology|June 2, 2010
Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthmaWilliam W Busse, Rohit Katial, David Gossage, et al.
Journal of Asthma and Allergy|April 10, 2024
Benralizumab in Severe Eosinophilic Asthma and Chronic Rhinosinusitis with Nasal Polyps: The Real-World, Multi-Country RANS Observational StudyTham T Le, Benjamin Emmanuel, Rohit Katial, et al.
The Journal of Allergy and Clinical Immunology|August 21, 2013
IL-4 confers resistance to IL-27-mediated suppression on CD4+ T cells by impairing signal transducer and activator of transcription 1 signalingZhihong Chen, Shanze Wang, Nkiruka Erekosima, et al.
The AAPS Journal|March 12, 2015
International Guidelines for Bioequivalence of Locally Acting Orally Inhaled Drug Products: Similarities and DifferencesDongmei Lu, Sau L Lee, Robert A Lionberger, et al.
Immunotherapy|February 11, 2025
Benralizumab in severe eosinophilic asthma by biologic use and key clinical subgroups: real-world XALOC-1 programme: a plain language summary of publicationDavid J Jackson, Girolamo Pelaia, Benjamin Emmanuel, et al.
The European Respiratory Journal|April 4, 2024
Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programmeDavid J Jackson, Girolamo Pelaia, Benjamin Emmanuel, et al.
The Journal of Allergy and Clinical Immunology|September 1, 2012
Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & ImmunologyJordan S Orange, Mark Ballow, E Richard Stiehm, et al.
Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
The Journal of Allergy and Clinical Immunology. in Practice|April 20, 2026
Dupilumab sustains efficacy despite LABA and ICS withdrawal in patients with asthma: a post hoc analysisMichael E Wechsler, Arnaud Bourdin, Klaus F Rabe, et al.
The Journal of Allergy and Clinical Immunology|July 23, 2013
Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophiliaMichel Laviolette, David L Gossage, Gail Gauvreau, et al.
The Journal of Allergy and Clinical Immunology|January 23, 2018
Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthmaSteven F Weinstein, Rohit Katial, Shyamalie Jayawardena, et al.
The Journal of Allergy and Clinical Immunology|June 2, 2010
Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthmaWilliam W Busse, Rohit Katial, David Gossage, et al.
Journal of Asthma and Allergy|April 10, 2024
Benralizumab in Severe Eosinophilic Asthma and Chronic Rhinosinusitis with Nasal Polyps: The Real-World, Multi-Country RANS Observational StudyTham T Le, Benjamin Emmanuel, Rohit Katial, et al.
The Journal of Allergy and Clinical Immunology|August 21, 2013
IL-4 confers resistance to IL-27-mediated suppression on CD4+ T cells by impairing signal transducer and activator of transcription 1 signalingZhihong Chen, Shanze Wang, Nkiruka Erekosima, et al.
The AAPS Journal|March 12, 2015
International Guidelines for Bioequivalence of Locally Acting Orally Inhaled Drug Products: Similarities and DifferencesDongmei Lu, Sau L Lee, Robert A Lionberger, et al.
Immunotherapy|February 11, 2025
Benralizumab in severe eosinophilic asthma by biologic use and key clinical subgroups: real-world XALOC-1 programme: a plain language summary of publicationDavid J Jackson, Girolamo Pelaia, Benjamin Emmanuel, et al.
The European Respiratory Journal|April 4, 2024
Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programmeDavid J Jackson, Girolamo Pelaia, Benjamin Emmanuel, et al.
The Journal of Allergy and Clinical Immunology|September 1, 2012
Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & ImmunologyJordan S Orange, Mark Ballow, E Richard Stiehm, et al.
Pageof 7